Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors
Clinical trial NCT05894486 · UNKNOWN
Trial details
- NCT number
- NCT05894486
- Sponsor
- Peking University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-05
- Primary completion
- 2025-06-05
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.